Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.

Kimble JB, Malherbe DC, Meyer M, Gunn BM, Karim MM, Ilinykh PA, Iampietro M, Mohamed KS, Negi S, Gilchuk P, Huang K, Wolf YI, Braun W, Crowe JE, Alter G, Bukreyev A.

J Virol. 2019 Feb 5;93(4). pii: e01845-18. doi: 10.1128/JVI.01845-18. Print 2019 Feb 15.

2.

Role of Transmembrane Protein 16F in the Incorporation of Phosphatidylserine Into Budding Ebola Virus Virions.

Younan P, Iampietro M, Santos RI, Ramanathan P, Popov VL, Bukreyev A.

J Infect Dis. 2018 Nov 22;218(suppl_5):S335-S345. doi: 10.1093/infdis/jiy485. Erratum in: J Infect Dis. 2019 Jan 29;219(4):677.

PMID:
30289531
3.

Disruption of Phosphatidylserine Synthesis or Trafficking Reduces Infectivity of Ebola Virus.

Younan P, Iampietro M, Santos RI, Ramanathan P, Popov VL, Bukreyev A.

J Infect Dis. 2018 Nov 22;218(suppl_5):S475-S485. doi: 10.1093/infdis/jiy489.

PMID:
30289506
4.

Combined HDAC and BET Inhibition Enhances Melanoma Vaccine Immunogenicity and Efficacy.

Badamchi-Zadeh A, Moynihan KD, Larocca RA, Aid M, Provine NM, Iampietro MJ, Kinnear E, Penaloza-MacMaster P, Abbink P, Blass E, Tregoning JS, Irvine DJ, Barouch DH.

J Immunol. 2018 Nov 1;201(9):2744-2752. doi: 10.4049/jimmunol.1800885. Epub 2018 Sep 24.

5.

Ebola Virus Shed Glycoprotein Triggers Differentiation, Infection, and Death of Monocytes Through Toll-Like Receptor 4 Activation.

Iampietro M, Santos RI, Lubaki NM, Bukreyev A.

J Infect Dis. 2018 Nov 22;218(suppl_5):S327-S334. doi: 10.1093/infdis/jiy406.

PMID:
30085081
6.

Disabling of lymphocyte immune response by Ebola virus.

Younan P, Iampietro M, Bukreyev A.

PLoS Pathog. 2018 Apr 12;14(4):e1006932. doi: 10.1371/journal.ppat.1006932. eCollection 2018 Apr. No abstract available.

7.

Immunogenicity and Cross-Reactivity of Rhesus Adenoviral Vectors.

Iampietro MJ, Larocca RA, Provine NM, Abbink P, Kang ZH, Bricault CA, Barouch DH.

J Virol. 2018 May 14;92(11). pii: e00159-18. doi: 10.1128/JVI.00159-18. Print 2018 Jun 1.

8.

Ebola Virus Binding to Tim-1 on T Lymphocytes Induces a Cytokine Storm.

Younan P, Iampietro M, Nishida A, Ramanathan P, Santos RI, Dutta M, Lubaki NM, Koup RA, Katze MG, Bukreyev A.

MBio. 2017 Sep 26;8(5). pii: e00845-17. doi: 10.1128/mBio.00845-17.

9.

Ebola virus glycoprotein directly triggers T lymphocyte death despite of the lack of infection.

Iampietro M, Younan P, Nishida A, Dutta M, Lubaki NM, Santos RI, Koup RA, Katze MG, Bukreyev A.

PLoS Pathog. 2017 May 22;13(5):e1006397. doi: 10.1371/journal.ppat.1006397. eCollection 2017 May.

10.

Adenovirus serotype 5 vaccine vectors trigger IL-27-dependent inhibitory CD4+ T cell responses that impair CD8+ T cell function.

Larocca RA, Provine NM, Aid M, Iampietro MJ, Borducchi EN, Badamchi-Zadeh A, Abbink P, Ng'ang'a D, Bricault CA, Blass E, Penaloza-MacMaster P, Stephenson KE, Barouch DH.

Sci Immunol. 2016 Nov;1(5). pii: eaaf7643. doi: 10.1126/sciimmunol.aaf7643. Epub 2016 Nov 4.

11.

The Ebola Interferon Inhibiting Domains Attenuate and Dysregulate Cell-Mediated Immune Responses.

Lubaki NM, Younan P, Santos RI, Meyer M, Iampietro M, Koup RA, Bukreyev A.

PLoS Pathog. 2016 Dec 8;12(12):e1006031. doi: 10.1371/journal.ppat.1006031. eCollection 2016 Dec.

12.

Development of novel replication-defective lymphocytic choriomeningitis virus vectors expressing SIV antigens.

Penaloza MacMaster P, Shields JL, Alayo QA, Cabral C, Jimenez J, Mondesir J, Chandrashekar A, Cabral JM, Lim M, Iampietro MJ, Provine NM, Bricault CA, Seaman M, Orlinger K, Aspoeck A, Fuhrmann G, Lilja AE, Monath T, Mangeat B, Pinschewer DD, Barouch DH.

Vaccine. 2017 Jan 3;35(1):1-9. doi: 10.1016/j.vaccine.2016.11.063. Epub 2016 Nov 26.

13.

Vaccine protection against Zika virus from Brazil.

Larocca RA, Abbink P, Peron JP, Zanotto PM, Iampietro MJ, Badamchi-Zadeh A, Boyd M, Ng'ang'a D, Kirilova M, Nityanandam R, Mercado NB, Li Z, Moseley ET, Bricault CA, Borducchi EN, Giglio PB, Jetton D, Neubauer G, Nkolola JP, Maxfield LF, De La Barrera RA, Jarman RG, Eckels KH, Michael NL, Thomas SJ, Barouch DH.

Nature. 2016 Aug 25;536(7617):474-8. Epub 2016 Jun 28.

14.

Construction and evaluation of novel rhesus monkey adenovirus vaccine vectors.

Abbink P, Maxfield LF, Ng'ang'a D, Borducchi EN, Iampietro MJ, Bricault CA, Teigler JE, Blackmore S, Parenteau L, Wagh K, Handley SA, Zhao G, Virgin HW, Korber B, Barouch DH.

J Virol. 2015 Feb;89(3):1512-22. doi: 10.1128/JVI.02950-14. Epub 2014 Nov 19.

15.

Human herpesvirus 6B immediate-early I protein contains functional HLA-A*02, HLA-A*03, and HLA-B*07 class I restricted CD8(+) T-cell epitopes.

Iampietro M, Morissette G, Gravel A, Dubuc I, Rousseau M, Hasan A, O'Reilly RJ, Flamand L.

Eur J Immunol. 2014 Dec;44(12):3573-84. doi: 10.1002/eji.201444931. Epub 2014 Oct 29.

16.

Inhibition of interleukin-2 gene expression by human herpesvirus 6B U54 tegument protein.

Iampietro M, Morissette G, Gravel A, Flamand L.

J Virol. 2014 Nov;88(21):12452-63. doi: 10.1128/JVI.02030-14. Epub 2014 Aug 13.

17.

Inhibition of breast cancer cell proliferation through disturbance of the calcineurin/NFAT pathway by human herpesvirus 6B U54 tegument protein.

Iampietro M, Gravel A, Flamand L.

J Virol. 2014 Nov;88(21):12910-4. doi: 10.1128/JVI.02107-14. Epub 2014 Aug 13.

18.

Hypoxia and inflammation in children with sickle cell disease: implications for hippocampal functioning and episodic memory.

Iampietro M, Giovannetti T, Tarazi R.

Neuropsychol Rev. 2014 Jun;24(2):252-65. doi: 10.1007/s11065-014-9259-4. Epub 2014 Apr 18. Review.

PMID:
24744195
19.

Involvement of angiopoietin-like 4 in matrix remodeling during chondrogenic differentiation of mesenchymal stem cells.

Mathieu M, Iampietro M, Chuchana P, Guérit D, Djouad F, Noël D, Jorgensen C.

J Biol Chem. 2014 Mar 21;289(12):8402-12. doi: 10.1074/jbc.M113.539825. Epub 2014 Feb 6.

20.

Alternative serotype adenovirus vaccine vectors elicit memory T cells with enhanced anamnestic capacity compared to Ad5 vectors.

Penaloza-MacMaster P, Provine NM, Ra J, Borducchi EN, McNally A, Simmons NL, Iampietro MJ, Barouch DH.

J Virol. 2013 Feb;87(3):1373-84. doi: 10.1128/JVI.02058-12. Epub 2012 Nov 14.

21.

First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001).

Baden LR, Walsh SR, Seaman MS, Tucker RP, Krause KH, Patel A, Johnson JA, Kleinjan J, Yanosick KE, Perry J, Zablowsky E, Abbink P, Peter L, Iampietro MJ, Cheung A, Pau MG, Weijtens M, Goudsmit J, Swann E, Wolff M, Loblein H, Dolin R, Barouch DH.

J Infect Dis. 2013 Jan 15;207(2):240-7. doi: 10.1093/infdis/jis670. Epub 2012 Nov 2.

22.

Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001).

Barouch DH, Liu J, Peter L, Abbink P, Iampietro MJ, Cheung A, Alter G, Chung A, Dugast AS, Frahm N, McElrath MJ, Wenschuh H, Reimer U, Seaman MS, Pau MG, Weijtens M, Goudsmit J, Walsh SR, Dolin R, Baden LR.

J Infect Dis. 2013 Jan 15;207(2):248-56. doi: 10.1093/infdis/jis671. Epub 2012 Nov 2.

23.

Empirically defined patterns of executive function deficits in schizophrenia and their relation to everyday functioning: a person-centered approach.

Iampietro M, Giovannetti T, Drabick DA, Kessler RK.

Clin Neuropsychol. 2012;26(7):1166-85. doi: 10.1080/13854046.2012.721399. Epub 2012 Oct 4.

24.

Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys.

Teigler JE, Iampietro MJ, Barouch DH.

J Virol. 2012 Sep;86(18):9590-8. doi: 10.1128/JVI.00740-12. Epub 2012 Jul 11.

25.

Accelerated heterologous adenovirus prime-boost SIV vaccine in neonatal rhesus monkeys.

Liu J, Li H, Iampietro MJ, Barouch DH.

J Virol. 2012 Aug;86(15):7829-35. doi: 10.1128/JVI.00512-12. Epub 2012 May 16.

26.

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys.

Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, Iampietro MJ, SanMiguel A, Seaman MS, Ferrari G, Forthal DN, Ourmanov I, Hirsch VM, Carville A, Mansfield KG, Stablein D, Pau MG, Schuitemaker H, Sadoff JC, Billings EA, Rao M, Robb ML, Kim JH, Marovich MA, Goudsmit J, Michael NL.

Nature. 2012 Jan 4;482(7383):89-93. doi: 10.1038/nature10766.

27.

Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection.

Bradley RR, Lynch DM, Iampietro MJ, Borducchi EN, Barouch DH.

J Virol. 2012 Jan;86(1):625-9. doi: 10.1128/JVI.06254-11. Epub 2011 Nov 9.

28.

Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions.

Bradley RR, Maxfield LF, Lynch DM, Iampietro MJ, Borducchi EN, Barouch DH.

J Virol. 2012 Jan;86(2):1267-72. doi: 10.1128/JVI.06165-11. Epub 2011 Nov 9.

29.

Clinical utility of the Boston Naming Test in predicting ultimate side of surgery in patients with medically intractable temporal lobe epilepsy: A double cross-validation study.

Busch RM, Frazier TW, Iampietro MC, Chapin JS, Kubu CS.

Epilepsia. 2009 May;50(5):1270-3. doi: 10.1111/j.1528-1167.2008.01865.x. Epub 2008 Nov 17.

30.

Multivariate neuropsychological prediction of seizure lateralization in temporal epilepsy surgical cases.

Keary TA, Frazier TW, Busch RM, Kubu CS, Iampietro M.

Epilepsia. 2007 Aug;48(8):1438-46. Epub 2007 Apr 18.

Supplemental Content

Loading ...
Support Center